In vitro and In vivo Functions of SARS-CoV-2 Infection-enhancing and Neutralizing Antibodies

SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques.

Citing Articles

NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants.

Gui Q, Wang H, Liu C, Li W, Zhou B, Tang S Virol J. 2025; 22(1):45.

PMID: 39994733 PMC: 11849304. DOI: 10.1186/s12985-025-02667-0.

Antibody-dependent enhancement of coronaviruses.

Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.

PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.

Antibody-dependent enhancement of ORFV uptake into host cells.

Tang X, Zhang C, Geng Q, Chen D, Ma W Virulence. 2025; 16(1):2466503.

PMID: 39954287 PMC: 11834454. DOI: 10.1080/21505594.2025.2466503.

Tracking Immunity: An Increased Number of COVID-19 Boosters Increases the Longevity of Anti-RBD and Anti-RBD-Neutralizing Antibodies.

Hou C, Williams S, Boyle V, Roeder A, Bobbett B, Garcia I Vaccines (Basel). 2025; 13(1).

PMID: 39852840 PMC: 11769131. DOI: 10.3390/vaccines13010061.

Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19.

Nakayama E, Shioda T Pathogens. 2025; 13(12.

PMID: 39770368 PMC: 11728538. DOI: 10.3390/pathogens13121109.

References

Edwards R, Mansouri K, Stalls V, Manne K, Watts B, Parks R . Cold sensitivity of the SARS-CoV-2 spike ectodomain. Nat Struct Mol Biol. 2021; 28(2):128-131. PMC: 7878407. DOI: 10.1038/s41594-020-00547-5. View

Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W . Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812-827.e19. PMC: 7332439. DOI: 10.1016/j.cell.2020.06.043. View

Baum A, Fulton B, Wloga E, Copin R, Pascal K, Russo V . Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020; 369(6506):1014-1018. PMC: 7299283. DOI: 10.1126/science.abd0831. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Sempowski G, Saunders K, Acharya P, Wiehe K, Haynes B . Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Cell. 2020; 181(7):1458-1463. PMC: 7250787. DOI: 10.1016/j.cell.2020.05.041. View

Brouwer P, Caniels T, van der Straten K, Snitselaar J, Aldon Y, Bangaru S . Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020; 369(6504):643-650. PMC: 7299281. DOI: 10.1126/science.abc5902. View

Liao H, Levesque M, Nagel A, Dixon A, Zhang R, Walter E . High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods. 2009; 158(1-2):171-9. PMC: 2805188. DOI: 10.1016/j.jviromet.2009.02.014. View

Pak J, Sharon C, Satkunarajah M, Auperin T, Cameron C, Kelvin D . Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain. J Mol Biol. 2009; 388(4):815-23. PMC: 7094495. DOI: 10.1016/j.jmb.2009.03.042. View

Hansen J, Baum A, Pascal K, Russo V, Giordano S, Wloga E . Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020; 369(6506):1010-1014. PMC: 7299284. DOI: 10.1126/science.abd0827. View

10.

Naldini L, Blomer U, Gage F, Trono D, Verma I . Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 1996; 93(21):11382-8. PMC: 38066. DOI: 10.1073/pnas.93.21.11382. View

11.

Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A . Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020; 584(7821):437-442. PMC: 7442695. DOI: 10.1038/s41586-020-2456-9. View

12.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

13.

Hui K, Cheung M, Perera R, Ng K, Bui C, Ho J . Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med. 2020; 8(7):687-695. PMC: 7252187. DOI: 10.1016/S2213-2600(20)30193-4. View

14.

Yip M, Leung H, Li P, Cheung C, Dutry I, Li D . Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med J. 2016; 22(3 Suppl 4):25-31. View

15.

Haynes B, Corey L, Fernandes P, B Gilbert P, Hotez P, Rao S . Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020; 12(568). DOI: 10.1126/scitranslmed.abe0948. View

16.

Shi R, Shan C, Duan X, Chen Z, Liu P, Song J . A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020; 584(7819):120-124. DOI: 10.1038/s41586-020-2381-y. View

17.

Kint J, Maier H, Jagt E . Quantification of infectious bronchitis coronavirus by titration in vitro and in ovo. Methods Mol Biol. 2015; 1282:89-98. PMC: 7121424. DOI: 10.1007/978-1-4939-2438-7_9. View

18.

Leist S, Dinnon 3rd K, Schafer A, Tse L, Okuda K, Hou Y . A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell. 2020; 183(4):1070-1085.e12. PMC: 7510428. DOI: 10.1016/j.cell.2020.09.050. View

19.

Zost S, Gilchuk P, Chen R, Case J, Reidy J, Trivette A . Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020; 26(9):1422-1427. PMC: 8194108. DOI: 10.1038/s41591-020-0998-x. View

20.

Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L . Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020; 182(1):73-84.e16. PMC: 7231725. DOI: 10.1016/j.cell.2020.05.025. View